CN Patent

CN102048677B — 一种盐酸缬更昔洛韦固体制剂及其制备方法

Assigned to Hainan Poly Pharm Co ltd · Expires 2014-03-05 · 12y expired

What this patent protects

本发明涉及一种盐酸缬更昔洛韦固体制剂及其制备方法。本发明所述的盐酸缬更昔洛韦固体制剂，包括：(1)盐酸缬更昔洛韦；(2)高分子材料；(3)制剂辅料。安全性高、吸收好、生物利用度高，现有的更昔洛韦一般采取静脉注射方式使用，本发明给患者提供了更好的选择，避免了注射引起的一些安全问题及患者的痛苦。

USPTO Abstract

本发明涉及一种盐酸缬更昔洛韦固体制剂及其制备方法。本发明所述的盐酸缬更昔洛韦固体制剂，包括：(1)盐酸缬更昔洛韦；(2)高分子材料；(3)制剂辅料。安全性高、吸收好、生物利用度高，现有的更昔洛韦一般采取静脉注射方式使用，本发明给患者提供了更好的选择，避免了注射引起的一些安全问题及患者的痛苦。

Drugs covered by this patent

valganciclovir-hydrochloride (VALGANCICLOVIR HYDROCHLORIDE)

Patent Metadata

Patent number: CN102048677B
Jurisdiction: CN
Classification: —
Expires: 2014-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Hainan Poly Pharm Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.